Zunsemetinib is a Small Molecule owned by Aclaris Therapeutics, and is involved in 9 clinical trials, of which 5 were completed, 3 are ongoing, and 1 is planned.

Zunsemetinib (ATI-450, CDD-450) acts as dual specificity mitogen activated protein kinase kinase 2 inhibitor. Dual specificity mitogen activated protein kinase kinase 2 play a critical role in mitogen growth factor signal transduction. It regulates the MK2-PI pathway which is responsible for activation of inflammatory enzymes such as COX-2, iNOS and production of inflammatory cytokines. The drug candidate inhibits the activity of dual specificity mitogen activated protein kinase kinase 2 and inhibits production of inflammatory cytokines by locking MK2 in a catalytically inactive state.

The revenue for Zunsemetinib is expected to reach a total of $2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Zunsemetinib NPV Report.

Zunsemetinib was originated by Confluence Life Sciences and is currently owned by Aclaris Therapeutics.

Zunsemetinib Overview

Zunsemetinib (ATI-450, CDD-450) is under development for the treatment of pyoderma gangrenosum, chronic inflammation, psoriasis, psoriatic arthritis, inflammatory bowel disease, crohn's colitis, rheumatoid arthritis, and hidradenitis suppurativa and, metastatic breast cancer and chemotherapy-induced bone loss, pancreatic cancer and gout. It is administered through oral route. The drug candidate targets MAP2K2 which regulates MK2-PI pathway. The drug candidate is developed based on KINect platform technology which works by identifying protein kinase inhibiting drugs using structure based drug design.

The drug candidate was also under development for the treatment of neutrophilic dermatosis, Cryopyrin-associated periodic syndromes like familial cold autoinflammatory syndrome, muckle-wells syndrome, or neonatal onset multisystem inflammatory disease.

Aclaris Therapeutics Overview

Aclaris Therapeutics is bio-pharmaceutical company focused on identifying, developing and commercializing small molecule therapies for immuno-inflammatory conditions. Its lead product, ESKATA is a proprietary formulation of high-concentration hydrogen peroxide topical solution prescribed for the treatment of raised seborrheic keratosis (SK). The company’s pipeline products include A-101, ATI-1777-oral JAK 1/3 inhibitor, ATI-501, ATI-450-oral MK2 pathway inhibitor, soft JAK inhibitor, ITK oral anti-IL17 and ITK topical anti-IL17.Aclaris Therapeutics’ pipeline products are used for the treatment of common warts, alopecia areata, androgenetic alopecia, psoriasis, arthritis, gangrenosum, inflammatory bowel disease and atopic dermatitis. The company also develops investigational drugs to treat skin and hair conditions. Aclaris Therapeutics is headquartered in Wayne, Pennsylvania, the US.

The company reported revenues of (US Dollars) US$6.8 million for the fiscal year ended December 2021 (FY2021), an increase of 4.3% over FY2020. The operating loss of the company was US$89.7 million in FY2021, compared to an operating loss of US$50.9 million in FY2020. The net loss of the company was US$90.9 million in FY2021, compared to a net loss of US$51 million in FY2020. The company reported revenues of US$19 million for the third quarter ended September 2022, compared to a revenue of US$1.5 million the previous quarter.

Quick View – Zunsemetinib

Report Segments
  • Innovator
Drug Name
  • Zunsemetinib
Administration Pathway
  • Oral
Therapeutic Areas
  • Dermatology
  • Gastrointestinal
  • Genetic Disorders
  • Immunology
  • Infectious Disease
  • Musculoskeletal Disorders
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.